New hope for ovarian cancer patients out of options
NCT ID NCT07340164
Summary
This study is for people with recurrent ovarian cancer that has progressed after treatment with a specific type of maintenance therapy (PARP inhibitors). It aims to see if a newer, targeted drug called trastuzumab deruxtecan works better than standard chemotherapy. The drug specifically targets a protein called HER2, which some ovarian cancers have. About 116 participants will be randomly assigned to receive either the new drug or the standard chemotherapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Yonsei University Health System, Severance Hospital
Seoul, Seoul, 03722, South Korea
Conditions
Explore the condition pages connected to this study.